studies

breast cancer - HER2-positive, lapatinib plus capecitabine vs. trastuzumab emtansine, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsEMILIA, 2012 (REV) 1.47 [1.18; 1.83] 1.47[1.18; 1.83]EMILIA, 2012 (REV)10%991NAnot evaluable deaths (OS) (extension)detailed resultsEMILIA, 2012 (REV) 1.33 [1.14; 1.56] 1.33[1.14; 1.56]EMILIA, 2012 (REV)10%991NAnot evaluable progression or deaths (PFS)detailed resultsEMILIA, 2012 (REV) 1.54 [1.30; 1.82] 1.54[1.30; 1.82]EMILIA, 2012 (REV)10%991NAnot evaluable objective responses (ORR)detailed resultsEMILIA, 2012 (REV) 0.58 [0.43; 0.77] 0.58[0.43; 0.77]EMILIA, 2012 (REV)10%786NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-06-03 11:35 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 1312

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons